Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advanced NSCLC: new cytostatic agents.

Paris A Kosmidis1, Christian Manegold

  • 1Medical Oncology Department, "Hygeia" Hospital, Athens Tsoha 2 street, Athens 11521, Greece. parkosmi@otenet.gr

Lung Cancer (Amsterdam, Netherlands)
|July 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SNF-CLIMEDIN: A Randomized Trial of Digital Support and Intervention in Patients With Advanced Non-Small Cell Lung Cancer. A Hellenic Cooperative Oncology Group Study.

JCO clinical cancer informatics·2026
Same author

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

A Systematic Review of Progress toward Unlocking the Power of Epigenetics in NSCLC: Latest Updates and Perspectives.

Cells·2023
Same author

Genetic Variations of <i>VEGFA</i> Gene Are Associated With Infiltration of Adjacent Tissues and the Clinical Outcome of Patients With Nasopharyngeal Carcinoma.

Anticancer research·2020

New cytostatic agents like oxaliplatin and epothilones are being studied for advanced non-small cell lung cancer. This review covers current data on these and other agents, including irinotecan and alimta.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced non-small cell lung cancer (NSCLC) presents significant treatment challenges.
  • Novel therapeutic strategies are crucial for improving patient outcomes.

Purpose of the Study:

  • To review current information on emerging cytostatic agents for advanced NSCLC.
  • To provide an overview of oxaliplatin, epothilones, irinotecan, and alimta.

Main Methods:

  • Literature review of recent clinical and preclinical studies.
  • Synthesis of data on efficacy, safety, and mechanism of action.

Main Results:

  • Oxaliplatin, epothilones, irinotecan, and alimta show promise as novel treatments.
  • These agents are being investigated in both first- and second-line settings.

Related Experiment Videos

Conclusions:

  • Emerging cytostatic agents offer new therapeutic avenues for advanced NSCLC.
  • Further research is warranted to establish optimal use and efficacy.